Paclitaxel eluting coronary balloon dilatation catheter
The novel reliable DCB
Improved transition lumen
Pt/Ir MRO markers
Hydrax plus
Ensure low drug loss, quick transfer and more retention time in the artery:
Ultrasound pule to break the solution into uniform nanodrops
Spray dosage system that provides a homogenous drug distribution.
Minimizes drug loss while navigating to the lesion, reduce the coating stress and the risk of cracking.
Process to create paclitaxel microcrystals, which can be transferred fast and maintain more time.
Conclusion: the use of the Essential for treating de-novo coronary lesions in small coronary vessels was safe and associated with low rates of clinical events at the 12-month follow-up.
EffPac 5-year has been presented at LINC 2022 by Prof Ulf Teichgräber.
Main Investigator: Dr Josep Rodés-Cabau (PI), Quebec Heart and Lung Institute (Quebec, CAN)
In this study, the drug-coated balloon Essential showed a good efficacy in the treatment of ISR (mostly of DES) in terms of OCT and QCA assessment, which appear to be comparable to the provided by other drug-coated balloons well supported by clinical evidence.
Main Investigator: José M. de la Torre Hernandez, Universitary Hospital Marqués de Valdecilla, (Santander, SPA)
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.